We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiation...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.135 | 4.05405405405 | 3.33 | 3.5999 | 3.06 | 116436 | 3.28698908 | CS |
4 | -1.215 | -25.9615384615 | 4.68 | 5.13 | 3.06 | 140788 | 3.75503656 | CS |
12 | -5.925 | -63.0990415335 | 9.39 | 9.789 | 3.06 | 135267 | 5.78128508 | CS |
26 | -13.315 | -79.3504171633 | 16.78 | 18.01 | 3.06 | 128236 | 9.07844364 | CS |
52 | -21.825 | -86.2989323843 | 25.29 | 40.98 | 3.06 | 132974 | 16.81211332 | CS |
156 | -2.535 | -42.25 | 6 | 40.98 | 3.06 | 130294 | 17.39472646 | CS |
260 | -2.535 | -42.25 | 6 | 40.98 | 3.06 | 130294 | 17.39472646 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions